India's First Unique Lab-To-Market Drug To Be Launched by Cadila
This article was originally published in PharmAsia News
Executive Summary
India's first new chemical entity to move from laboratory to market, Cadila Healthcare's Lipaglyn (saroglitazar), for treating diabetes, has a launch target after being approved in India as a blockbuster drug expected to reap $1 billion in global annual sales.